Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-09-21 4:34 pm Purchase |
2021-09-20 | 13G | Protagonist Therapeutics, Inc. PTGX |
Point72 Asset Management, L.P. | 4,329,030 9.100% |
4,329,030 (New Position) |
Filing History |
| 2021-02-17 2:23 pm Sale |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
Consonance Capital Management LP | 2,729,709 6.380% |
-3,328,796 (-54.94%) |
Filing History |
| 2021-02-16 2:22 pm Purchase |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
Consonance Capital Management LP | 6,058,505 9.990% |
6,058,505 (New Position) |
Filing History |
| 2021-02-12 9:17 pm Purchase |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 4,274,965 9.990% |
1,942,335 (+83.27%) |
Filing History |
| 2021-02-12 6:42 pm Purchase |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
FARALLON CAPITAL MANAGEMENT LLC | 3,925,000 9.000% |
1,071,902 (+37.57%) |
Filing History |
| 2021-02-12 09:36 am Purchase |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
RTW Investments, LP | 3,650,069 8.670% |
1,190,081 (+48.38%) |
Filing History |
| 2021-02-11 08:05 am Sale |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
ADAGE CAPITAL PARTNERS GP LLC | 1,150,045 2.690% |
-1,049,955 (-47.73%) |
Filing History |
| 2021-02-08 10:31 am Purchase |
2021-02-05 | 13G | Protagonist Therapeutics, Inc. PTGX |
FMR CORP | 6,452,764 15.079% |
2,371,797 (+58.12%) |
Filing History |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BLACKROCK INC BLK |
2,591,711 6.200% |
935,470 (+56.48%) |
Filing History |
| 2021-02-01 5:41 pm Unchanged |
2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
JOHNSON & JOHNSON JNJ |
2,449,183 5.700% |
0 (Unchanged) |
Filing History |
| 2020-06-09 4:32 pm Purchase |
2020-05-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
BLACKROCK INC BLK |
1,656,241 4.800% |
94,284 (+6.04%) |
Filing History |
| 2020-06-08 4:04 pm Sale |
2020-05-11 | 13D | Protagonist Therapeutics, Inc. PTGX |
Lilly Ventures Fund I LLC | 1,559,060 4.500% |
-540,422 (-25.74%) |
Filing History |
| 2020-05-22 4:30 pm Purchase |
2020-05-13 | 13G | Protagonist Therapeutics, Inc. PTGX |
ADAGE CAPITAL PARTNERS GP LLC | 2,200,000 6.390% |
2,200,000 (New Position) |
Filing History |